March 31, 2020

Artio Medical Receives Financing to Support Regulatory Pathway for the Solus Gold Embolization Device

March 31, 2020—Artio Medical, Inc. announced it has closed an additional $8.8 million in Series A financing, bringing the total capital raised to date to more than $20 million.

The company advised that the additional funds will support Artio’s initiative to obtain FDA 510(k) clearance to market the Solus Gold embolization device in the United States.

According to Artio Medical, the Solus Gold embolization device, developed for peripheral vascular embolization, is a metal implant designed to provide a solid barrier to blood flow through damaged or diseased blood vessels. The device combines a low-profile flexible delivery system and a detachable gold metal implant that is designed for passage through tortuous blood vessels, precise placement, and immediate vessel occlusion after placement of a single device.

The company develops endovascular products for the treatment of peripheral vascular, neurovascular, and structural heart disease.


April 2, 2020

European and Asia-Pacific Societies Provide Joint Checklist for Interventional Radiology Services to Manage COVID-19

March 30, 2020

SVIN Announces Virtual Spring Conference